ResTORbio announced on Friday 15th that its current phase 3 drug trial for respiratory tract infections did not achieve its primary goal. The drug showed promise in earlier phases of testing, but sadly failed to reduce the incidence of respiratory tract infections in patients aged 65 and above. A setback for RTB101 This news has…

Researchers have discovered a new drug that targets the mTOR pathway, which is involved in aging and metabolism. It could function as a caloric restriction mimetic, bringing about similar health benefits. The mTOR pathway The mechanistic target of rapamycin (mTOR) pathway is a part of metabolism and is one of the four major pathways that…

Rapamycin is a promising anti-aging therapeutic derived from a bacterium that was first found on Easter Island (it’s named for Rapa Nui, the official name of Easter Island). It inhibits mTOR (mechanistic target of rapamycin), thus inhibiting the immune system response that would, in some cases, lead to organ rejection. This is the on-label, FDA-approved…

© 2018 - LIFE EXTENSION ADVOCACY FOUNDATION
Privacy Policy / Terms Of Use

       Powered by MMD